Susie Norris, MD
Endocrinology, Diabetes & Metabolism · Mount Vernon, WANPI 1417979667
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $10,524 of the $11,940 with a category attached, or 88.1%. Novo Nordisk AS accounts for 89.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $11,498 and has fallen 99.8% since, to $22 in 2025.
Across 79 payments — averaging $151.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$11K
- Boston Scientific$239
- Johnson & Johnson$133
- Novo Nordisk$117
- Lilly USA, LLC$97
- Amgen$89
- plus $612 from 17 others
What the payments were for
- Travel & lodging$10,52488%
- Food & beverage$1,41012%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 5 | $10,653 |
| Boston Scientific | 7 | $239 |
| Johnson & Johnson | 12 | $133 |
| Novo Nordisk | 9 | $117 |
| Lilly USA, LLC | 5 | $97 |
| Amgen | 5 | $89 |
| Sanofi-aventis U.S. LLC | 4 | $68 |
| Dexcom, Inc. | 3 | $67 |
| Tandem Diabetes Care, Inc. | 4 | $67 |
| Radius Health, Inc. | 3 | $52 |
| Mannkind Corporation | 3 | $43 |
| Boehringer Ingelheim | 2 | $38 |
| Pfizer | 3 | $36 |
| Corcept Therapeutics | 2 | $35 |
| IBSA Pharma Inc. | 2 | $31 |
| AbbVie | 2 | $28 |
| Merck | 2 | $27 |
| Zimmer Biomet | 1 | $25 |
| BETA Bionics, Inc. | 1 | $22 |
| Averitas Pharma Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $19 |
| Valeritas, Inc. | 1 | $19 |
| AstraZeneca | 1 | $14 |
How this compares
$11,940 in reported general payments places this provider in the 85th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $152,954 |
| MounjaroTirzepatide | 67 | $78,155 |
| TrulicityDulaglutide | 43 | $65,347 |
| TymlosAbaloparatide | 22 | $58,016 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $28,444 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $25,578 |
| JardianceEmpagliflozin | 19 | $23,101 |
| FarxigaDapagliflozin Propanediol | 14 | $13,368 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $6,691 |
| Novolog FlexpenInsulin Aspart | 13 | $4,010 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,722 |
| Humalog Kwikpen U-100Insulin Lispro | 21 | $3,505 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 34 | $3,066 |
| SynthroidLevothyroxine Sodium | 12 | $1,619 |
| Hydrocortisone | 15 | $1,028 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $117 | $152,954120 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $97 | $144,386123 claims |
| Radius Health, Inc.Tymlos | $52 | $58,01622 claims |
| Boehringer IngelheimJardiance | $38 | $23,10119 claims |
| AstraZenecaFarxiga | $14 | $13,36814 claims |
| AbbVieSynthroid | $28 | $1,61912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
Other endocrinology, diabetes & metabolism in Mount Vernon
- Vince MontesMount Vernon$10K
- Emir GuvenMount Vernon$5K
- Michael ShannonLacey$698K
- Lynn KohlmeierSpokane$518K
- Carol WyshamSpokane$512K
- Bruce WilsonRichland$352K
- Irl HirschSeattle$192K
- Biju KunhiramanYakima$118K
- Nicole EhrhardtSeattle$111K
- Kristina UtzschneiderSeattle$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.